Alzheimer's Disease Trial, Recruiting NCT06827678 Sponsor: Huashan Hospital Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06827678
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with normal cognition (healthy volunteers):

  • People aged between 45 and 90 years old, any gender
  • People whose memory and thinking have been assessed as normal, with a Clinical Dementia Rating (CDR) score of 0
  • People confirmed by a researcher to have no neurological diseases, major long-term illnesses, cancer, or active infections
  • People with no family history of Alzheimer's disease or other conditions affecting memory, thinking, or movement
  • People who are able to understand and sign a written consent form before any assessments take place
  • Female participants must provide medical records showing surgical sterilisation (such as hysterectomy, removal of both ovaries, or tubal ligation), or confirmation of being past menopause for more than one year; those who could still become pregnant must use effective contraception throughout the study
  • Male participants must use effective contraception throughout the study and must not donate sperm during this time
  • People who are willing and able to follow all study procedures

For people with cognitive impairment:

  • People aged between 45 and 90 years old, any gender
  • People with a CDR score of 0.5 or higher
  • People with a Mini-Mental State Examination (MMSE) score of 24 or below
  • People whose brain MRI results support an Alzheimer's disease diagnosis, with no signs of other neurological conditions
  • People whose Alzheimer's-related medications have been at a stable dose for at least 30 days before joining the study
  • People who can provide written consent themselves, or whose legal guardian or carer can provide it on their behalf
  • People who may be accompanied by a carer if needed
  • Female participants must provide medical records confirming surgical sterilisation (such as hysterectomy, removal of both ovaries, or tubal ligation)

Who may not be able to join:

  • People with serious neurological conditions or significant disorders affecting the digestive, heart, liver, kidney, blood, cancer-related, hormonal, breathing, or immune systems
  • People with metal implants incompatible with MRI scans, such as pacemakers, metal devices in blood vessels, insulin pumps, cochlear implants, nerve stimulators, or brain aneurysm clips
  • People who cannot tolerate the noise of an MRI machine, or who have a history of claustrophobia (fear of enclosed spaces)
  • People who have been exposed to more than 50 mSv of ionising radiation in the past year through other research studies
  • People with a history of drug or alcohol misuse
  • People who are pregnant or currently breastfeeding
  • People whose veins are difficult to access, making repeated blood draws not possible
  • People who have used an experimental drug or device with unknown safety or effectiveness within the past month
  • People who are allergic to any ingredients in the imaging tracer injection used in the study
  • People who have any other condition that the study investigator believes could pose a risk or affect the study's results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Fang Xie, PhD, Huashan Hospital

Phone: +8613764308300

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Huashan Hospital
Registry
ClinicalTrials.gov
Start date
1 August 2022
Est. completion
30 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Evaluation of Synaptic Density in Alzheimer's Disease Using Synaptic Vesicle Glycoprotein 2A (SV2A) PET Tracer [¹⁸F]SDM-8; Evaluation of Neuronal Function in Alzheimer's Disease Using Metabotropic Glutamate Receptor 5 (mGluR5) PET Tracer [¹⁸F]PS232

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov